🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

25 recruiting trials

for Locally Advanced Biliary Tract Cancers

Alternating Chemo-immunotherapy and FGFR Inhibitor for FGFR-positive Biliary or Cholangiocarcinoma NCT07780838Phase 21 site📍 Columbus Ohio State University Comprehensive Cancer Center · Tests: Biospecimen Collection, Cisplatin, Computed Tomography, Durvalumab, Gemcitabine Adebrelimab Combined With Gemcitabine, Cisplatin, and Simvastatin for Advanced Biliary Tract Cancer NCT07392541Phase 1, Phase 21 site📍 Wuhan Tongji Hospital · Tests: Adebrelimab, Gemcitabine + Cisplatin, Simvastatin 20mg Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer NCT06467357Phase 3272 sites📍 Scottsdale📍 Tucson📍 Tucson AstraZeneca · Tests: Gemcitabine, Cisplatin, Durvalumab, Trastuzumab deruxtecan, Rilvegostomig Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor NCT05523947Phase 1, Phase 219 sites📍 Boston📍 Nashville📍 Adelaide Yuhan Corporation · Tests: YH32367 Combination Therapy of GCNT and Tislelizumab in Advanced Biliary Tract Cancer NCT06893380n/a1 site📍 Seongnam-si CHA University · Tests: Gemcitabine, Cisplatin, Nab-paclitaxel, and Tislelizumab. A Study of SHR-A1904 in Previous Systemic Treatment Failed Biliary Tract Cancer NCT07450976Phase 22 sites📍 Beijing📍 Shanghai Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Tests: SHR-A1904 for Injection Phase II Study of Trastuzumab Rezetecan Combined With Adebrelimab and Lenvatinib as First-Line Therapy for Advanced HER2-Positive/HER2-Low Biliary Tract Cancer NCT07670273Phase 21 site📍 Beijing Peking Union Medical College Hospital · Tests: Trastuzumab Rezetecan, Adebrelimab, Lenvatinib Neoadjuvant Chemotherapy for Locally Advanced Gall Bladder Cancer : a Randomized Control Trial (NEOGB) NCT06712420Phase 33 sites📍 Delhi📍 Delhi📍 Delhi Rajiv Gandhi Cancer Institute & Research Center, India · Tests: neoadjuvant chemotherapy, curative surgery A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors NCT05592626Phase 1, Phase 219 sites📍 Sacramento📍 Celebration📍 Miami Marengo Therapeutics, Inc. · Tests: STAR0602, Irinotecan (Camptosar), Docetaxel (Taxotere) Y-90 With Durvalumab/Gem/Cis in Intrahepatic Cholangio NCT05655949Phase 21 site📍 Boston Beth Israel Deaconess Medical Center · Tests: Gemcitabine, Cisplatin, Durvalumab, Yttrium-90 Clinical Trial of YH32364 in Patients With Locally Advanced or Metastatic EGFR Overexpressing Solid Tumors NCT06975410Phase 1, Phase 24 sites📍 Seoul📍 Seoul📍 Seoul Yuhan Corporation · Tests: YH32364 A Clinical Study of SHR-A1811 in the Treatment of HER2-positive Locally Advanced or Metastatic Biliary Tract Cancer NCT06778031Phase 22 sites📍 Harbin📍 Shanghai Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Tests: SHR-A1811, SHR-1316, SHR-8068 A Study of TQB2102 for Injection in the Treatment of HER2-positive Biliary Tract Cancer NCT06431490Phase 1, Phase 243 sites📍 Fuyang📍 Hefei📍 Hefei Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Phar… · Tests: TQB2102 for injection The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) NCT04585750Phase 1, Phase 276 sites📍 Irvine📍 La Jolla📍 Los Angeles PMV Pharmaceuticals, Inc · Tests: rezatapopt, pembrolizumab Gemcitabine, Cisplatin, Nab-paclitaxel (GAP) and Cemiplimab for Locally Advanced Biliary Tract Cancer (BTC) NCT07433673Phase 21 site📍 New York Columbia University · Tests: Cemiplimab Olanzapine for the Management of Cancer Associated Appetite Loss in Patients With Advanced Esophagogastric, Hepatopancreaticobiliary, Colorectal or Lung Cancer NCT05705492Phase 21 site📍 Portland OHSU Knight Cancer Institute · Tests: Olanzapine, Placebo Administration, Questionnaire Administration A Study of BL-M07D1 Versus Physician's Choice of Chemotherapy in Patients With HER2-expressing Locally Advanced or Metastatic Biliary Tract Cancer After Platinum-containing Chemotherapy Failure NCT07606599Phase 32 sites📍 Hefei📍 Beijing Sichuan Baili Pharmaceutical Co., Ltd. · Tests: BL-M07D1, Oxaliplatin, Calcium levofolinate, Fluorouracil, Irinotecan Hydrochloride Liposome A Study on the Prevalence of Clinically Useful Mutations in Solid Tumor Characterized by Next Generation Sequencing Methods on Liquid Biopsy Analysis (POPCORN) NCT06028724n/a1 site📍 Aviano Centro di Riferimento Oncologico - Aviano Trastuzumab in Combination With Serplulimab and Chemotherapy for the Treatment of HER2-overexpressing Unresectable Locally Advanced or Metastatic Biliary Tract Cancer or Urothelial Carcinoma After Failure of Standard Therapy NCT07506057Phase 21 site📍 Shenyang Xiujuan Qu · Tests: Trastuzumab+Serplulimab Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC NCT05733598Phase 212 sites📍 Beverly Hills📍 La Jolla📍 Miami Replimune, Inc. · Tests: RP2, Bevacizumab, Atezolizumab, Durvalumab, RP2 Monotherapy AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001) NCT07038343Phase 1, Phase 227 sites📍 Gilbert📍 Los Angeles📍 Los Angeles Avenzo Therapeutics, Inc. · Tests: AVZO-1418, Combination Agent 1, Combination Agent 2 Liposomal Irinotecan Plus 5-FU/LV and Sintilimab With Sequential SBRT for Locally Advanced Biliary Tract Cancer NCT07797816Phase 21 site📍 Nanjing The Affiliated Nanjing Drum Tower Hospital of Nanjing Unive… · Tests: Irinotecan Hydrochloride Liposome Injection (II), Fluorouracil, Leucovorin, Sintilimab, Stereotactic Body Radiation The… Testing Ivonescimab Versus FOLFOX in Advanced Biliary Tract Cancer Patients NCT06529718Phase 242 sites📍 Amiens📍 Angers📍 Avignon UNICANCER · Tests: Ivonescimab, FOLFOX regimen A Study Comparing BL-B01D1 With Treatment of Physician's Choice in Patients With Locally Advanced or Metastatic Biliary Tract Cancer After Failure of Platinum-based Chemotherapy(PANKU-BTC01) NCT07582315Phase 31 site📍 Beijing Sichuan Baili Pharmaceutical Co., Ltd. · Tests: BL-B01D1, Oxaliplatin, Calcium levofolinate, Fluorouracil, Irinotecan Hydrochloride Liposome Phase II Study of Trastuzumab Rezetecan Combined With Adebrelimab and Lenvatinib in Advanced HER2-Positive/Low-Expression Biliary Tract Cancer NCT07704177Phase 21 site📍 Beijing Peking Union Medical College Hospital · Tests: Trastuzumab Rezetecan, Adebrelimab, Lenvatinib
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy